Related Experiment Video
Updated: Jan 24, 2026

The Other End of the Leash: An Experimental Test to Analyze How Owners Interact with Their Pet Dogs
Published on: October 13, 2017
Analgesia during Monkeypox Virus Experimental Challenge Studies in Prairie Dogs (Cynomys ludovicianus)
Christina L Hutson1, Nadia Gallardo-Romero2, Darin S Carroll2
1Centers for Disease Control and Prevention, The University of Georgia, Athens, Georgia; The University of Georgia, Athens, Georgia; Georgia;,
Abstract:
Because human patients with monkeypox virus (MPXV) infection report painful symptoms, it is reasonable to assume that animals infected with MPXV experience some degree of pain. Understanding whether and how analgesics affect MPXV disease progression is crucial when planning in vivo challenge experiments. In the current study, we challenged prairie dogs with a low dose (4 ×10³ pfu) of MPXV and treated with meloxicam (NSAID) or buprenorphine (opioid); control animals did not receive analgesia or received analgesia without MPXV challenge. Subsets of animals from each group were serially euthanized during the course of the study. Disease progression and viral kinetics were similar between groups, but MXPVinfected, meloxicam-treated animals showed increasing trends of morbidity and mortality compared with other groups. Differences between no-analgesia MPXV-infected control animals and MPXV-infected animals treated with buprenorphine were minimal. The findings in the current study allow more informed decisions concerning the use of analgesics during experimental MPXV challenge studies, thereby improving animal welfare. In light of these findings, we have modified our pain scale for this animal model to include the use of buprenorphine for pain relief when warranted after MPXV challenge.
Insights
Monkeypox virus (MPXV) infection in prairie dogs suggests pain. Meloxicam increased morbidity, while buprenorphine showed minimal impact, informing analgesic use in MPXV studies.
Area of Science:
- Veterinary Medicine
- Virology
- Animal Welfare
Background:
- Monkeypox virus (MPXV) infection causes pain in humans, suggesting similar experiences in infected animals.
- Understanding analgesic effects on MPXV disease progression is vital for experimental design and animal welfare.
Purpose of the Study:
- To investigate the impact of analgesics (meloxicam and buprenorphine) on MPXV disease progression in prairie dogs.
- To inform decisions regarding analgesic use in MPXV challenge studies.
Main Methods:
- Prairie dogs were infected with MPXV and treated with meloxicam (NSAID) or buprenorphine (opioid).
- Control groups received no analgesia or analgesia without MPXV challenge.
- Animals were serially euthanized to monitor disease progression and viral kinetics.
Main Results:
- MPXV disease progression and viral kinetics were similar across groups.
- MPXV-infected animals treated with meloxicam showed increased morbidity and mortality trends.
- MPXV-infected animals treated with buprenorphine exhibited minimal differences compared to non-analgesia controls.
Conclusions:
- Meloxicam may negatively impact MPXV disease progression in prairie dogs.
- Buprenorphine appears to be a safe analgesic option for MPXV-infected animals.
- Findings support informed analgesic use in MPXV research, enhancing animal welfare and modifying pain assessment scales.
Related Concept Videos
Analgesia and Pain Management
What are Viruses?
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs
Experimental Determination of Chemical Formula
Experimental Designs
Experimental RNAi

